Texas Biotechnology Corporation

Encysive Pharmaceuticals, Inc.

Pfizer Corporation

Brian Dupre

Chengde Wu

Timothy P Kogan

Ian Leslie Scott

Jamal M Kassir

George W Holland

Ronald J Biediger

Robert V Market

Karin M Keller

Daxin Gao

Pamela J Beck

Huong Dao

Huong Bui

Jie Chen

Eric Anderson

Keith Allen Monk

Brandon M Young

Michael M Savage

E Radford Decker

Pedro Lory

Reginald L Tennyson

Junmei Wang

Kathy L Wheeler

Noel Nguyen

Linda K Hamaker

C Eric Anderson

Raymond J Kessler

Eric C Anderson

Keith A Monk

Reginald Tennyson

Provided are compounds that are modulators of CCR9 receptor activity, compositions containing the compounds and methods of use of the compounds and compositions. In certain embodiments, provided are methods for treating or ameliorating diseases associated with modulation of CCR9 receptor activity.

Modulators of CCR9 receptor and methods of use thereof

The present invention relates to urotensin II receptor antagonists, pharmaceutical compositions containing them and their use.

Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists

Propanoic acid derivatives that inhibit the binding of integrins to their receptors

Di- and trivalent small molecule selectin inhibitors

This invention relates to compounds that inhibit the binding of E-selectin or P-selectin to sialyl-Lewis.sup.x or sialyl-Lewis.sup.a presented on a cell surface having the general structure: ##STR1## This invention also relates to methods of inhibiting the binding of E-selectin or P-selectin to sialyl-Lewis.sup.x or sialyl-Lewis.sup.a presented on a cell surface using said compounds and to pharmaceutically active compositions comprising compounds that inhibit the binding of E-selectin to sialyl-Lewis.sup.x and to methods of treatment of septic shock, ARDS, Crohn's disease, chronic inflammatory diseases, such as psoriasis and rheumatoid arthritis, and reperfusion injuries that occurs following heart attacks, strokes and organ transplants and to the treatment of cancer.

Compositions and methods of inhibiting the binding of E-selectin or

This invention relates to compounds that inhibit the binding of E-selectin and/or P-selectin to sialyl-Lewis.sup.x or sialyl-Lewis.sup.a presented on a cell surface having the general structure ##STR1## wherein X is selected from the group consisting of --(CH.sub.2).sub.n CO.sub.2 H, --O(CH.sub.2).sub.m CO.sub.2 H, --(CH.sub.2).sub.n O(CH.sub.2).sub.m CO.sub.2 H, --CONH(CH.sub.2).sub.m CO.sub.2 H, --CH(OZ)(CO.sub.2 H), --CH(Z)(CO.sub.2 H), --(CH.sub.2).sub.n SO.sub.3 H, --(CH.sub.2).sub.n PO.sub.3 D.sub.1 D.sub.2, --NH(CH.sub.2).sub.m CO.sub.2 H, --CONH(CHR.sub.6)CO.sub.2 H, (1-H-tetrazolyl-5-alkyl-), and --OH;

Binding of E-selectin or P-selectin to sialyl Lewis.sup.x or

Growing community of inventors

Houston, TX, United States of America

Brian Dupre